Related Experiment Videos
Is the stage set for lymphoid tissue replacement in active lepromatous leprosy patients?
Leprosy in India
|January 1, 1977
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Survivin targeting triple-fusion vaccine DCSurvivin-LTB inhibits tumor growth in mouse model of triple-negative breast cancer.
Medical oncology (Northwood, London, England)·2025
Expression, purification and characterization of a novel triple fusion protein developed for the immunotherapy of survivin positive cancers.
Protein expression and purification·2024
Combination immunotherapy with Survivin and luteinizing hormone-releasing hormone fusion protein in murine breast cancer model.
World journal of clinical oncology·2019
Immunotherapy approach with recombinant survivin adjuvanted with alum and MIP suppresses tumor growth in murine model of breast cancer.
Preparative biochemistry & biotechnology·2018
Development of a novel recombinant LHRH fusion protein for therapy of androgen and estrogen dependent cancers.
Protein expression and purification·2017
Study of lymph node biopsies in lepromatous leprosy patients under treatment.
Leprosy in India·1983
Clinico-pathological study of lymph node involvement in leprosy.
Leprosy in India·1983
Short course treatment of tuberculoid cases--a feasibility study.
Leprosy in India·1983
The effect of clofazimine on liver function tests in lepra reaction (ENL).
Leprosy in India·1983
Cryptococcosis in immunocompromised patients without HIV infection: experience of a hospital in Chile.
Revista iberoamericana de micologia·2026
Diagnostic Yield and Cost of Morphology-Guided Immunohistochemistry in Liver Tumors.
Asian Pacific journal of cancer prevention : APJCP·2026
Single-cell transcriptomic profiling of cerebrospinal fluid reveals immune-cell heterogeneity and multicompartment MIF/CD74-related communication in tuberculous and purulent meningitis.
Frontiers in cellular and infection microbiology·2026
Persistent CD8+ T-cell activation (HLA-DR/CD38) as an immunological marker in antiretroviral-treated human immunodeficiency virus-1 patients: A cross-sectional study.
The Journal of international medical research·2026